

This communication should be viewed by:

- Primary Care Providers
- Behavioral Health Providers
- Clinical staff
- Specialist
- Claims and Billing Department
- Facility/Practice staff

Pharmaceutical Policy Updates Effective January 1, 2025

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at mvphealthcare.com and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective January 1, 2025, and will be available for viewing on or before December 1, 2024. Hard copies of the policies are available upon request.

| Pharmaceutical Policy Name | Status |
|---|---------------------|
| Multiple Sclerosis Agents Part B | Updated |
| Ozanimod (Zeposia) | Updated |
| GABA Receptor Modulators | Updated |
| Daybue | Updated |
| Radicava | Updated |
| Radicava Part B | Updated |
| Spravato | Updated |
| Spravato Part B | Updated |
| Select Hypnotics | Updated |
| Gabapentin ER | Updated |
| Oral Allergen Immunotherapy Medications | Reviewed/No Changes |
| Respiratory Syncytial Virus/Synagis | Reviewed/No Changes |
| Nuedexta | Updated |
| Agents for female sexual dysfunction | Updated |

To view all communications, visit mvphealthcare.com/FastFax

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.



| | |
|--|---------------------|
| Biosimilar, Select Medical | Archived |
| Duchenne Muscular Dystrophy | Updated |
| Medicare Part B Drug Therapy | Reviewed/No Changes |
| Medicare Part B Step Therapy | Reviewed/No Changes |
| Monoclonal Antibodies for Alzheimer's Disease | Updated |
| Monoclonal Antibodies for Alzheimer's Disease- Part B | Updated |
| Palforzia | Updated |
| Prostate Cancer | Updated |
| Select Antipsychotics | Updated |
| Spinal Muscular Atrophy | Updated |
| Zoladex-Medicaid | Reviewed/No Changes |
| Zulresso | Updated |
| Zulresso Part B | Updated |
| Entyvio | Updated |
| Guselkumab | Updated |
| Medicare Part B vs. Part D Determination | Updated |
| Pharmacy Management Programs External (Effective 11/01/2024) | Updated |

To view all faxed messages, visit mvphealthcare.com/FastFax.

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

